Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and Pfizer. Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average ...
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback